6981-18-6Relevant articles and documents
Ormetoprim synthesis method
-
, (2017/11/16)
The invention provides an ormetoprim synthesis method. The method includes steps: subjecting p-cresol and dimethyl carbonate to phenolic hydroxymethylation to obtain a compound I; subjecting the compound I and potassium bromide to bromination reaction under an acetic anhydride-nitric acid system to obtain a compound II; taking cuprous chloride as a catalyst, and subjecting the compound II and sodium methylate methanol solution to methoxylation reaction to obtain a compound III; subjecting the compound III and a VHA reagent to formylation reaction to obtain a compound IV; subjecting the compound IV to reaction with sodium methylate and acrylonitrile methanol solution to obtain a compound V; after the compound V is subjected to alkali isomerization to obtain a vinyl ether structure, subjecting to addition reaction with methyl alcohol and direct condensation and cyclization with guanidine to finally obtain a compound VI which is a final product namely ormetoprim. Defects in the prior art are overcome, and the provided ormetoprim synthesis method has advantages of technical simplicity, easiness in acquisition of starting materials, high yield and low production cost.
Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X3/P2X2/3 antagonist for the treatment of pain
Carter, David S.,Alam, Muzaffar,Cai, Haiying,Dillon, Michael P.,Ford, Anthony P.D.W.,Gever, Joel R.,Jahangir, Alam,Lin, Clara,Moore, Amy G.,Wagner, Paul J.,Zhai, Yansheng
scheme or table, p. 1628 - 1631 (2009/11/30)
P2X purinoceptors are ligand-gated ion channels whose endogenous ligand is ATP. Both the P2X3 and P2X2/3 receptor subtypes have been shown to play an important role in the regulation of sensory function and dual P2X3/P2X2/3 antagonists offer significant potential for the treatment of pain. A high-throughput screen of the Roche compound collection resulted in the identification of a novel series of diaminopyrimidines; subsequent optimization resulted in the discovery of RO-4, a potent, selective and drug-like dual P2X3/P2X2/3 antagonist.
Diaminopyrimidines as P2X3 and P2X2/3 antagonists
-
Page/Page column 89, (2010/02/14)
Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.